Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Esophagogastric Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2019
A Phase 2 Study of Zolbetuximab as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma Whose Tumors Have High or Intermediate Claudin 18.2 Expression
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2019
A Phase 2 Multi-Center Study of SM-88 in Patients with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2019
A Phase 3, Randomized, Double-Blind, Clinical Trial of Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction Adenocarcinoma
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 10, 2019
DORA Trial: Phase 3 Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 13, 2019
A Single-Arm, Phase 2 Study to Evaluate the Safety and Efficacy of IMMU-132 in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 13, 2019
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 3, 2019
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 3, 2019
Efficacy and Safety of AbGn-168H in Patients with Moderate to Severe Active, Anti-TNFα and/or Anti-integrin Refractory Ulcerative Colitis: A 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 3, 2019
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 10, 2019